BIA Says NHS Funding Changes Would Jeopardize Life Science Sector, As UK PM Announces ‘Hard’ Brexit
Executive Summary
As prime minister Theresa May confirms that the UK is to leave the EU single market, the BioIndustry Association has warned that proposals by NICE and NHS England to change funding arrangements for innovative drugs risks impairing the competitiveness of the UK life sciences sector.
You may also be interested in...
Europe's Pharma Tries To 'Keep Calm And Carry On' Amid Storm Strikes
Pharma leaders in the UK and Europe have had a stormy start to the week, as the UK government revealed its aim to leave the single market and the OECD issued a loud call for drug makers to restrain their prices.
NHS England/NICE Consultation Could Spell Market Access Complications
Companies with innovative and expensive drugs may face additional hurdles to get their products to the market in England, according to a consultation from NICE, England's health technology appraisal institute, and NHS England.
UK Industry Urges Quick Adoption Of Accelerated Access Proposals As Brexit Clouds Gather
UK review proposes key changes to the way that new medicines and medical technologies are identified, developed and adopted for use in the National Health Service, including an Accelerated Access Partnership of stakeholders that will manage the accelerated pathway to patients, a new government unit to discuss commercial arrangements, and a “transformative designation” to flag up products of greatest interest.